Azevan Pharmaceuticals

Azevan Pharmaceuticals is focused on developing innovative therapeutics for Central Nervous System (CNS) disorders, particularly targeting stress-related and neurodegenerative conditions through advanced clinical trials. Azevan Pharmaceuticals develops therapeutics aimed at addressing CNS disorders. The company is headquartered in Bethlehem, US. Neal Simon is the CEO.

Azevan has secured USD 2. 21 mn in its latest funding round, Series C, from Ascent Biomedical Ventures on October 17, 2013, bringing the total amount raised to USD 2. 21 mn, with a current valuation of USD 34. 07 mn.

Azevan Pharmaceuticals specializes in creating therapeutics for CNS disorders, particularly stress and neurodegeneration. The flagship product, SRX246, is a selective vasopressin 1a receptor antagonist, undergoing clinical trials for conditions such as Intermittent Explosive Disorder and irritability associated with Huntington’s Disease. These trials focus on adult patients with severe neuropsychiatric symptoms across multiple US sites, aiming to provide effective treatment options in markets where existing therapies are inadequate. Operating within a clinical stage framework, Azevan Pharmaceuticals concentrates on the development and testing of its candidates rather than commercial sales.

Revenue generation is expected to occur through partnerships and licensing agreements post-regulatory approval. Collaborations with research institutions and healthcare providers are ongoing, including a partnership with the Department of Defense for a PTSD trial. Upon successful FDA approval, Azevan plans to engage in direct sales to healthcare providers and managed care organizations in targeted markets. Azevan Pharmaceuticals plans to leverage the USD 2.

21 mn raised from its Series C funding to support the advancement of SRX246 and other therapeutic candidates. The company aims to expand its clinical trials and collaboration efforts into new markets, particularly focusing on regions with high prevalence of CNS disorders by 2024. The continued development of its innovative therapeutics is central to Azevan's growth strategy.